Lead area
Neurology
Our core focus, and the majority of our pipeline.
4 of 6programs in development
Specialty pharmaceutical company
Reformulating Patient Experience, Not Just Medicines.
BIOVERIC is building a pipeline of patient-centric medicines,
led by Neurology and extending into Cardiovascular and Antiviral care.
6Programs in
development
development
20+Patent applications
filed
filed
2024Founded in
Princeton, NJ
Princeton, NJ
Focus
Neurology first. Extending wherever patients need more.
We concentrate on conditions where the experience of treatment matters as much as the medicine itself, including rare conditions.
Extending into
Cardiovascular
Programs in specialty cardiovascular care.
Extending into
Antiviral
Programs in specialty and hospital antiviral care.
Our approach
Patient-first by design. Protected by our own IP.
20+patent applications filed
Our own intellectual property
BIOVERIC's programs are supported by more than twenty pending patent applications, including PCT international applications and U.S. provisional and non-provisional utility applications.
Designed around the patient experience
We look at how a medicine is given, how often, and how it fits into daily life, and design each program around the experience of the patient.
Built for the people who give care
Programs designed to simplify preparation and administration for caregivers, pharmacists and hospital teams.
Selected with rigour
Every program was chosen through a two-year evaluation of patient need, commercial potential and intellectual property.
A defined regulatory path
Our programs are intended for development through the FDA's 505(b)(2) pathway.
Pipeline
A focused, neurology-led portfolio.
Development stage reflects the most advanced activity for each program.
Program
Area
FeasibilityFeasibilityDevelopmentDev.ClinicalClinicalFDA filingFilingApprovalApproval
Status
B300
Neurology
Development
Current stage: Development
B400
Neurology
Development
Current stage: Development
B500
Neurology
Development
Current stage: Development
B600
Neurology
Development
Current stage: Development
B200
Cardiovascular
Development
Current stage: Development
B100
Antiviral
Development
Current stage: Development
All programs shown are investigational product candidates. They have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency, and their safety and effectiveness have not been established.
About
Patients notice every detail of a medicine. So do we.
BIOVERIC was founded in Princeton, NJ in 2024 on a simple conviction: every program should begin with the experience of the patient and caregiver, and work back to the medicine.
“Every program starts with one question: what would make this treatment easier or better to live with?”
Sandip Patel
Founder & Chief Executive Officer
Sandip founded BIOVERIC to put the patient experience at the center of how serious conditions are treated. A pharmaceutical scientist by training, he has spent his career in drug development, with prior roles at Astellas Pharma, Iveric Bio, Navinta, Sun Pharma and Zydus Lifesciences.
He holds a Master of Science in Pharmaceutics and an MBA, and leads BIOVERIC's programs from the company's Princeton, NJ headquarters.
Connect on LinkedIn →
Dr. Vijay Naringrekar
Scientific Advisor
Dr. Naringrekar brings more than three decades of pharmaceutical development experience built inside large pharmaceutical organizations such as American Cyanamid, Novartis, BMS and Celgene.
Across that career he has taken complex programs from early development through global scale-up and commercial supply, under the quality and regulatory standards that large-pharma programs demand.
Read the announcement →
Contact
Start a conversation.
Whether you're a potential partner, investor or member of the press, reach us directly by email or phone — we'll get back to you.
Phone
+1 (609) 431 0287Headquarters
303A College Rd East, Princeton, NJ 08540